Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes KIELPIN, Poland, June 22, 2021 (GLOBE NEWSWIRE) -- Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2...

Celon Pharma Hosting a Virtual Capital Markets Day on Wednesday, April 21st KIELPIN, Poland, April 19, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced that it will host a virtual Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET. The...

Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial KIELPIN, Poland, April 01, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL’280. This agent is in...

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was...

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation)...